Tuesday, February 06, 2024 9:40:00 PM
Compared to fast food e.g. there is the model where the mother company makes everything centrally and ships e.g. their burger patties and french fries, to the franchisee outlets for them to just cook and sell. Otherwise, franchise 'mothers' might license recipes and let the outlets make their own. The former model gives the mother company full control over the uniformity and quality of the product. I agree with you that NWBO wouldn't like to be in the business of selling or leasing Eden units because they want full control, make all the vaccines themselves and get the full price of the vaccine directly from the patients. Of course with no chance of somebody getting hold of their own Eden units and then going rogue with the whole thing business of production and sales in competition with NWBO.
In any case, we don't need to try to torture out the details of NWBO's business model going forward from one word that may have been thrown out casually by LP without trying to depict anything specific about the business model. We can only wait and see how NWBO unfolds the business going forward. One very clear thing IMO is that the eventual profit stream from brain cancers alone is likely to be very big to incredible yet it will take time to develop to the level where the $ needed for more clinical trials can come out of the cash flow of that business. To get more trials going significant capital participation from somebody(ies) is required asap. Hopefully, NWBO can come up with some form of partnership or other that doesn't require selling a large equity share of NWBO now at a cheap valuation. We can be sure that LP is working out just how to do that. The time is ripe for expanding posthaste in all strategic directions to finally speed up the expansion of their franchise. IMO it would be beyond ridiculous to not get things moving a heck of a lot faster than they have moved so far.
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM